Julphar Announces Entry into Oncology Market
- Agreement signed with Russia’s leading biotechnology company
- Products used to treat range of cancers including breast cancer
- Launch of medicines in UAE to improve access to cancer treatments
Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has announced its entry into the oncology market through a license and supply agreement with Russia’s leading biotechnology company, BIOCAD.
Julphar will be partnering with BIOCAD and Health Authorities to register three leading specialized products to the UAE, which are used to treat breast cancer, B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, colon cancer, lung cancer and glioblastoma.
Commenting on the announcement, Jerome Carle, General Manager of Julphar, said: “We are delighted to be partnering with BIOCAD in the UAE market as they have a proven track record and they support our core values. Entering the oncology market is a huge step forward for Julphar.
“It will enable us to continue to focus on delivering healthcare solutions that make a real difference to people’s lives.”
Cancer is one of the biggest health burdens in the UAE. According to a report issued last month by the World Health Organization’s (WHO) International Agency for Research on Cancer (IARC), breast cancer accounted for more than 20 per cent of the total 4,707 new cancer cases that were found in the UAE in 2018.
“Cancer can be a very costly illness, placing a considerable financial burden on families,” added Carle.
“With the launch of these products in the local market, we would like to ensure that as many people as possible have access to life-saving medicines. When patients choose Julphar they can rest assured that they are consistently receiving high quality, safe and effective products.”
Dmitry Morozov, CEO of BIOCAD, said: "Access to international markets is the number one priority of our company. That's why we consider our cooperation with one of the largest pharmaceutical companies in the Middle East a turning point in our international business development not only in the United Arab Emirates, but also the Middle East and North Africa region (MENA) in general.
“Moreover, medicines produced by BIOCAD are competitive in their effectiveness as well as the price. Therefore, the presence of Russian innovative drugs in the UAE will help make important biological therapies widely accessible to patients.
“We are glad our products will increase access to treatment of the most severe types of cancer for more patients in the UAE than before.”